• Login
    • Advanced search
    • Title
    • Channel
    • Module
  • Home
  • Client Solutions
    • Digital Transformation
    • Energy Transition
    • Supply Chains
    • Sustainability and ESG
    • Workforce Redesign
  • Sectors
    • Consumer Goods & Retail
    • Energy, Mining & Infrastructure
    • Financial Institutions
    • Healthcare & Life Sciences
    • Industrials, Manufacturing & Transportation
    • Technology
  • Learning Resources
    • Podcasts
    • Video Chats
    • Webinars
  • Area of Law
    • Antitrust & Competition
    • Artificial Intelligence
    • Banking & Finance
    • Capital Markets
    • Cybersecurity & Data Privacy
    • Data & Technology
    • Dispute Resolution
    • Employment & Compensation
    • Environment & Climate Change
    • Financial Services Regulatory
    • Inclusion, Diversity & Equity
    • Intellectual Property
    • International Commercial & Trade
    • Investigations, Compliance & Ethics
    • Mergers & Acquisitions
    • Pensions
    • Private Equity
    • Projects
    • Real Estate
    • Restructuring & Insolvency
    • Tax
  • Location
    • International

    • International
    • Asia Pacific

    • Australia
    • China
    • Hong Kong
    • Indonesia
    • Japan
    • Malaysia
    • South Korea (Korea, Republic of)
    • Singapore
    • Taipei
    • Thailand
    • Philippines
    • Vietnam
    • EMEA

    • Austria
    • Bahrain
    • Belgium
    • Czech Republic
    • Egypt
    • EU
    • France
    • Germany
    • Hungary
    • Italy
    • Kazakhstan
    • Luxembourg
    • Morocco
    • Netherlands
    • Poland
    • Portugal
    • Qatar
    • Russian Federation
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Türkiye
    • Ukraine
    • United Arab Emirates
    • United Kingdom
    • North America

    • Canada
    • United States
    • Latin America

    • Argentina
    • Brazil
    • Colombia
    • Chile
    • Mexico
    • Peru
    • Venezuela
Baker McKenzie InsightPlus Home
      • Title
      • Channel
      • Module
    • Hit ENTER to search in content
    • Advanced search
    • Login
  • Home
  • Client Solutions
    • Digital Transformation
    • Energy Transition
    • Supply Chains
    • Sustainability and ESG
    • Workforce Redesign
  • Sectors
    • Consumer Goods & Retail
    • Energy, Mining & Infrastructure
    • Financial Institutions
    • Healthcare & Life Sciences
    • Industrials, Manufacturing & Transportation
    • Technology
  • Learning Resources
    • Podcasts
    • Video Chats
    • Webinars
  • Area of Law
    • Antitrust & Competition
    • Artificial Intelligence
    • Banking & Finance
    • Capital Markets
    • Cybersecurity & Data Privacy
    • Data & Technology
    • Dispute Resolution
    • Employment & Compensation
    • Environment & Climate Change
    • Financial Services Regulatory
    • Inclusion, Diversity & Equity
    • Intellectual Property
    • International Commercial & Trade
    • Investigations, Compliance & Ethics
    • Mergers & Acquisitions
    • Pensions
    • Private Equity
    • Projects
    • Real Estate
    • Restructuring & Insolvency
    • Tax
  • Location
    • International

    • International
    • Asia Pacific

    • Australia
    • China
    • Hong Kong
    • Indonesia
    • Japan
    • Malaysia
    • South Korea (Korea, Republic of)
    • Singapore
    • Taipei
    • Thailand
    • Philippines
    • Vietnam
    • EMEA

    • Austria
    • Bahrain
    • Belgium
    • Czech Republic
    • Egypt
    • EU
    • France
    • Germany
    • Hungary
    • Italy
    • Kazakhstan
    • Luxembourg
    • Morocco
    • Netherlands
    • Poland
    • Portugal
    • Qatar
    • Russian Federation
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Türkiye
    • Ukraine
    • United Arab Emirates
    • United Kingdom
    • North America

    • Canada
    • United States
    • Latin America

    • Argentina
    • Brazil
    • Colombia
    • Chile
    • Mexico
    • Peru
    • Venezuela
  1. Healthcare & Life Sciences
  2. Singapore: Greater integration of AI seen in Singapore's national healthcare strategy

Singapore: Greater integration of AI seen in Singapore's national healthcare strategy

30 Jun 2025    3 minute read
    • Share by email
    • Share on
    • Twitter
    • LinkedIn
    • Facebook
    • Google plus
    • Get link
    • Get QR Code
    • Download
    • Print
Sectors Healthcare & Life Sciences
AI Artificial Intelligence

In brief

On 16 June 2025, the Minister for Health spoke at Synapxe's inaugural AI Accelerate Conference, recognizing how technology has been driving changes that the Ministry of Health (MOH) is going to embark on — in particular, the advent of precision medicine and the use of AI. The health minister summarized the foundational groundwork that the government has laid to build Singapore's healthcare AI strategy and shared the MOH's vision for the future.


Contents

In more detail

The government has been laying the groundwork for its healthcare AI strategy with the following initiatives:

1. Health Empowerment Through Advance Learning and Intelligent eXchange (HEALIX)

HEALIX is a secure platform for anonymized clinical and socioeconomic data sharing to build and train AI models for healthcare. The infrastructural platform is ready, and public healthcare institutions have been successfully onboarded.

2. HealthX Innovation Sandbox

Synapxe set up the HealthX Innovation Sandbox, which replicates a real-world environment using synthetic and anonymized data generated by HEALIX. This allows start-ups and innovators to experiment and develop practical use cases.

3. The right regulatory approach

The MOH is setting up a regulatory sandbox for AI software-as-medical devices (AI-SaMDs), where licensed public healthcare institutions can deploy the devices in-house without a manufacturer's license or product registration. All public healthcare institutions under MOH will be considered as one system, which will mean that they would be able to deploy AI-SaMDs even without a manufacturer's license or product registration.

Following the foundation prepared by the government, the MOH shared use cases of AI in the healthcare industry, including the following:

  • Chest X-ray AI being used at Geylang Polyclinic to prioritize cases, with upcoming deployments at the National Centre for Infectious Diseases (for tuberculosis screening) and Woodlands Health (for bone fracture detection). The aim is for this capability to be rolled out nationally by end 2026.
  • Generative AI tools, such as SingHealth's Note Buddy, supporting over 2,100 healthcare workers in creating more than 16,000 clinical and administrative notes. All public healthcare institutions will be using such tools by the end of 2025.
  • HealthHub, an app that holds citizens' health records, will be consolidated with apps from Singapore's three healthcare clusters: Health Buddy, NHG Cares App and NUHS App.
  • HealthHub AI, a conversational AI-enhanced version of the national health app, is in beta testing and will offer multilingual, personalized health advice by end-2025.
  • Predictive AI models will underpin the next phase of Healthier SG, enabling early identification of individuals at risk of serious conditions such as stroke, cardiac arrest and kidney failure. This will support targeted preventive care and social prescribing.

Key takeaways

With a clear robust infrastructure (e.g., HEALIX and regulatory sandboxes) and an open vision to embrace the use of AI, it is likely that healthcare institutions will increasingly adopt AI in their delivery of healthcare services in Singapore. While this signals that Singapore will be a growing market for AI-SaMDs, the MOH cautions about the possible risks of AI, underscoring the importance for AI-SaMD developers to keep in mind industry best practices and regulatory guidance during the development of such AI.

* * * * *

LOGO_Wong&Leow_Singapore

© 2025 Baker & McKenzie. Wong & Leow. All rights reserved. Baker & McKenzie. Wong & Leow is incorporated with limited liability and is a member firm of Baker & McKenzie International, a global law firm with member law firms around the world. In accordance with the common terminology used in professional service organizations, reference to a "principal" means a person who is a partner, or equivalent, in such a law firm. Similarly, reference to an "office" means an office of any such law firm. This may qualify as "Attorney Advertising" requiring notice in some jurisdictions. Prior results do not guarantee a similar outcome.

Contact Information
Andy Leck
Principal
Singapore
Read my Bio
andy.leck@bakermckenzie.com
Ren Jun Lim
Principal
Singapore
Read my Bio
ren.jun.lim@bakermckenzie.com

Copyright © 2025 Baker & McKenzie. All rights reserved. Ownership: This documentation and content (Content) is a proprietary resource owned exclusively by Baker McKenzie (meaning Baker & McKenzie International and its member firms). The Content is protected under international copyright conventions. Use of this Content does not of itself create a contractual relationship, nor any attorney/client relationship, between Baker McKenzie and any person. Non-reliance and exclusion: All Content is for informational purposes only and may not reflect the most current legal and regulatory developments. All summaries of the laws, regulations and practice are subject to change. The Content is not offered as legal or professional advice for any specific matter. It is not intended to be a substitute for reference to (and compliance with) the detailed provisions of applicable laws, rules, regulations or forms. Legal advice should always be sought before taking any action or refraining from taking any action based on any Content. Baker McKenzie and the editors and the contributing authors do not guarantee the accuracy of the Content and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the Content. The Content may contain links to external websites and external websites may link to the Content. Baker McKenzie is not responsible for the content or operation of any such external sites and disclaims all liability, howsoever occurring, in respect of the content or operation of any such external websites. Attorney Advertising: This Content may qualify as “Attorney Advertising” requiring notice in some jurisdictions. To the extent that this Content may qualify as Attorney Advertising, PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME. Reproduction: Reproduction of reasonable portions of the Content is permitted provided that (i) such reproductions are made available free of charge and for non-commercial purposes, (ii) such reproductions are properly attributed to Baker McKenzie, (iii) the portion of the Content being reproduced is not altered or made available in a manner that modifies the Content or presents the Content being reproduced in a false light and (iv) notice is made to the disclaimers included on the Content. The permission to re-copy does not allow for incorporation of any substantial portion of the Content in any work or publication, whether in hard copy, electronic or any other form or for commercial purposes.

Delete Comment ?

Are you sure want to delete comment ?

Get link
Embed
Share by email
Get QR Code

Scan this QR Code to share this content

  •  
  •  
  •  
HighQ
Copyright Baker McKenzie 2025 | Disclaimers | Supplemental Privacy Statement